- Home
- HFRO vs VALN Comparison
HFRO vs VALN Comparison
Compare HFRO & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- VALN
- Stock Information
- Founded
- HFRO 2000
- VALN 2012
- Country
- HFRO United States
- VALN France
- Employees
- HFRO N/A
- VALN N/A
- Industry
- HFRO Finance/Investors Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HFRO Finance
- VALN Health Care
- Exchange
- HFRO Nasdaq
- VALN Nasdaq
- Market Cap
- HFRO 352.4M
- VALN 354.8M
- IPO Year
- HFRO N/A
- VALN 2021
- Fundamental
- Price
- HFRO $5.78
- VALN $6.24
- Analyst Decision
- HFRO
- VALN Strong Buy
- Analyst Count
- HFRO 0
- VALN 2
- Target Price
- HFRO N/A
- VALN $17.50
- AVG Volume (30 Days)
- HFRO 421.7K
- VALN 50.9K
- Earning Date
- HFRO 01-01-0001
- VALN 03-20-2025
- Dividend Yield
- HFRO 12.00%
- VALN N/A
- EPS Growth
- HFRO N/A
- VALN N/A
- EPS
- HFRO 1.23
- VALN N/A
- Revenue
- HFRO $44,535,929.00
- VALN $176,817,979.00
- Revenue This Year
- HFRO N/A
- VALN $24.66
- Revenue Next Year
- HFRO N/A
- VALN $9.67
- P/E Ratio
- HFRO $5.50
- VALN N/A
- Revenue Growth
- HFRO N/A
- VALN N/A
- 52 Week Low
- HFRO $5.92
- VALN $3.62
- 52 Week High
- HFRO $9.38
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- HFRO 62.41
- VALN 74.97
- Support Level
- HFRO $5.54
- VALN $5.17
- Resistance Level
- HFRO $5.69
- VALN $5.82
- Average True Range (ATR)
- HFRO 0.10
- VALN 0.24
- MACD
- HFRO 0.02
- VALN 0.14
- Stochastic Oscillator
- HFRO 93.45
- VALN 100.00
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. The company's portfolio of investments includes different industry investments such as Financial, Communication Services, Energy, Healthcare, Materials, and others.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.